MUFG Securities EMEA plc Has $13.65 Million Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Key Points

• MUFG Securities EMEA plc has reduced its stake in Gilead Sciences by 12.9%, now owning 121,799 shares, which make up approximately 0.3% of its investment portfolio.
• In recent insider trading, CFO Andrew D. Dickinson sold 2,500 shares while CEO Daniel Patrick O'day sold 10,000 shares, indicating a decrease in their ownership positions.
• Gilead Sciences reported $2.01 EPS for the last quarter, exceeding estimates, with a revenue of $7.08 billion, marking a 1.4% increase year-over-year.

MUFG Securities EMEA plc reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 12.9% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 121,799 shares of the biopharmaceutical company's stock after selling 18,012 shares during the quarter. Gilead Sciences comprises approximately 0.3% of MUFG Securities EMEA plc's portfolio, making the stock its 21st biggest position. MUFG Securities EMEA plc's holdings in Gilead Sciences were worth $13,648,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of GILD. Bridgewater Associates LP lifted its position in Gilead Sciences by 122.7% during the 4th quarter. Bridgewater Associates LP now owns 460,936 shares of the biopharmaceutical company's stock worth $42,577,000 after acquiring an additional 253,994 shares in the last quarter. Nissay Asset Management Corp Japan ADV grew its stake in shares of Gilead Sciences by 5.2% in the fourth quarter. Nissay Asset Management Corp Japan ADV now owns 284,243 shares of the biopharmaceutical company's stock worth $26,750,000 after purchasing an additional 14,009 shares in the last quarter. Golden State Wealth Management LLC boosted its stake in Gilead Sciences by 14.5% during the first quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company's stock valued at $97,000 after buying an additional 109 shares in the last quarter. Ontario Teachers Pension Plan Board lifted its holdings in shares of Gilead Sciences by 54.6% during the fourth quarter. Ontario Teachers Pension Plan Board now owns 37,051 shares of the biopharmaceutical company's stock valued at $3,422,000 after purchasing an additional 13,086 shares during the last quarter. Finally, Mufg Securities Americas Inc. purchased a new stake in Gilead Sciences in the 4th quarter worth about $1,699,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Tuesday, July 15th. The stock was sold at an average price of $111.03, for a total value of $277,575.00. Following the completion of the transaction, the chief financial officer directly owned 162,610 shares in the company, valued at approximately $18,054,588.30. This represents a 1.51% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $113.94, for a total value of $1,139,400.00. Following the transaction, the chief executive officer directly owned 605,725 shares of the company's stock, valued at approximately $69,016,306.50. This represents a 1.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 82,000 shares of company stock worth $8,984,175. 0.27% of the stock is owned by corporate insiders.

Gilead Sciences Trading Up 0.9%

Shares of NASDAQ GILD traded up $1.06 during midday trading on Monday, hitting $120.47. The stock had a trading volume of 7,947,966 shares, compared to its average volume of 6,157,586. The company's 50-day simple moving average is $110.93 and its 200 day simple moving average is $107.64. The firm has a market cap of $149.48 billion, a P/E ratio of 24.00, a price-to-earnings-growth ratio of 0.75 and a beta of 0.33. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. Gilead Sciences, Inc. has a fifty-two week low of $72.43 and a fifty-two week high of $121.38.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%. The company had revenue of $7.08 billion during the quarter, compared to analysts' expectations of $6.95 billion. During the same period in the prior year, the firm earned $2.01 earnings per share. Gilead Sciences's revenue for the quarter was up 1.4% compared to the same quarter last year. Research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be given a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.6%. Gilead Sciences's dividend payout ratio is currently 62.95%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Royal Bank Of Canada raised their price target on Gilead Sciences from $96.00 to $98.00 and gave the stock a "sector perform" rating in a research note on Friday. Cantor Fitzgerald started coverage on Gilead Sciences in a report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price objective on the stock. UBS Group increased their price objective on Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a report on Friday. Truist Financial raised Gilead Sciences from a "hold" rating to a "buy" rating and raised their target price for the company from $108.00 to $127.00 in a report on Friday. Finally, Needham & Company LLC raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 target price on the stock in a report on Friday, July 25th. Seven analysts have rated the stock with a hold rating, sixteen have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $114.82.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.